|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARHGEF35 |
Gene summary for ARHGEF35 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARHGEF35 | Gene ID | 445328 |
| Gene name | Rho guanine nucleotide exchange factor 35 | |
| Gene Alias | ARHGEF5L | |
| Cytomap | 7q35 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | A5YM69 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 445328 | ARHGEF35 | P91T-E | Human | Esophagus | ESCC | 1.57e-04 | 4.88e-01 | 0.1828 |
| 445328 | ARHGEF35 | P107T-E | Human | Esophagus | ESCC | 1.23e-15 | 3.22e-01 | 0.171 |
| 445328 | ARHGEF35 | P126T-E | Human | Esophagus | ESCC | 5.51e-05 | 4.26e-01 | 0.1125 |
| 445328 | ARHGEF35 | P127T-E | Human | Esophagus | ESCC | 4.73e-15 | 3.05e-01 | 0.0826 |
| 445328 | ARHGEF35 | P128T-E | Human | Esophagus | ESCC | 2.04e-10 | 3.66e-01 | 0.1241 |
| 445328 | ARHGEF35 | P130T-E | Human | Esophagus | ESCC | 3.36e-08 | 1.97e-01 | 0.1676 |
| 445328 | ARHGEF35 | C04 | Human | Oral cavity | OSCC | 3.56e-11 | 8.32e-01 | 0.2633 |
| 445328 | ARHGEF35 | C21 | Human | Oral cavity | OSCC | 3.26e-16 | 6.01e-01 | 0.2678 |
| 445328 | ARHGEF35 | C30 | Human | Oral cavity | OSCC | 2.66e-33 | 1.81e+00 | 0.3055 |
| 445328 | ARHGEF35 | C38 | Human | Oral cavity | OSCC | 1.17e-03 | 7.40e-01 | 0.172 |
| 445328 | ARHGEF35 | C43 | Human | Oral cavity | OSCC | 1.73e-02 | 1.73e-01 | 0.1704 |
| 445328 | ARHGEF35 | C46 | Human | Oral cavity | OSCC | 1.40e-10 | 4.62e-01 | 0.1673 |
| 445328 | ARHGEF35 | C51 | Human | Oral cavity | OSCC | 1.73e-06 | 5.37e-01 | 0.2674 |
| 445328 | ARHGEF35 | C57 | Human | Oral cavity | OSCC | 1.40e-10 | 4.90e-01 | 0.1679 |
| 445328 | ARHGEF35 | C06 | Human | Oral cavity | OSCC | 1.09e-06 | 1.25e+00 | 0.2699 |
| 445328 | ARHGEF35 | C08 | Human | Oral cavity | OSCC | 2.71e-66 | 1.27e+00 | 0.1919 |
| 445328 | ARHGEF35 | C09 | Human | Oral cavity | OSCC | 2.43e-04 | 2.97e-01 | 0.1431 |
| 445328 | ARHGEF35 | LN46 | Human | Oral cavity | OSCC | 9.13e-11 | 6.73e-01 | 0.1666 |
| 445328 | ARHGEF35 | SYSMH1 | Human | Oral cavity | OSCC | 3.92e-19 | 5.38e-01 | 0.1127 |
| 445328 | ARHGEF35 | SYSMH2 | Human | Oral cavity | OSCC | 4.62e-30 | 8.74e-01 | 0.2326 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARHGEF35 | SNV | Missense_Mutation | novel | c.241N>C | p.Glu81Gln | p.E81Q | A5YM69 | protein_coding | deleterious(0.02) | possibly_damaging(0.515) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| ARHGEF35 | SNV | Missense_Mutation | novel | c.671N>T | p.Pro224Leu | p.P224L | A5YM69 | protein_coding | tolerated(0.71) | benign(0.006) | TCGA-BH-A0C1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| ARHGEF35 | SNV | Missense_Mutation | c.1391C>A | p.Ser464Tyr | p.S464Y | A5YM69 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-D8-A1JL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ARHGEF35 | SNV | Missense_Mutation | rs553072768 | c.1285N>A | p.Val429Met | p.V429M | A5YM69 | protein_coding | tolerated(1) | benign(0.01) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| ARHGEF35 | SNV | Missense_Mutation | novel | c.1019C>T | p.Ser340Phe | p.S340F | A5YM69 | protein_coding | deleterious(0.01) | benign(0.358) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ARHGEF35 | SNV | Missense_Mutation | novel | c.1273G>A | p.Ala425Thr | p.A425T | A5YM69 | protein_coding | tolerated(0.44) | benign(0.006) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ARHGEF35 | SNV | Missense_Mutation | novel | c.841N>T | p.Asp281Tyr | p.D281Y | A5YM69 | protein_coding | deleterious(0) | possibly_damaging(0.629) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| ARHGEF35 | SNV | Missense_Mutation | c.1098G>T | p.Glu366Asp | p.E366D | A5YM69 | protein_coding | tolerated(0.15) | benign(0.041) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| ARHGEF35 | SNV | Missense_Mutation | rs553072768 | c.1285N>A | p.Val429Met | p.V429M | A5YM69 | protein_coding | tolerated(1) | benign(0.01) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ARHGEF35 | SNV | Missense_Mutation | c.1259A>G | p.Asp420Gly | p.D420G | A5YM69 | protein_coding | deleterious(0.01) | possibly_damaging(0.59) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |